Company Encyclopedia
View More
name
Akari Therap
AKTX.US
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells.
1.946 T
AKTX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Akari Therapeutics Provides Corporate Update

    Dec 4 (Reuters) - Akari Therapeutics PLC:* AKARI THERAPEUTICS PROVIDES CORPORATE UPDATE AND HIGHLIGHTS ITS ADC PAYLOAD INNOVATION EXPECTED TO DRIVE VALUE IN NEW CEO CORNER SEGMENT Source text: Further company coverage:

    Reuters·
    US
    AKTX
    0.00%
    Reuters·
    US
    AKTX
    0.00%

    U.S. Stock Movement Update: Kala Bio up 24%, Cantor Equity Partners up 14%, Symbotic down 12%

    The market overview of US stocks in the past hour shows that market sentiment fluctuates between the pharmaceutical and technology sectors, with pharmaceutical stocks performing particularly well. Kala Pharmaceuticals leads the way, indicating a preference for innovation in the pharmaceutical sector. Technology stocks, on the other hand, show divergence, with some individual stocks under pressure, as short-term funds seem to be searching for new breakthroughs. The overall pace is fast, with significant volatility, and short-term enthusiasm continues to rise. In the past hour, the stock with the largest movement is Kala Pharmaceuticals, which has become the market focus with a 24.32% increase, showing a clear influx of funds that has driven the stock price up rapidly. The active performance of the pharmaceutical sector appears to have sparked market interest in innovative drugs, with short-term sentiment running high. Strong stocks: 1. Cantor Equity Partners: up 13.94%, with significant fund inflow and investors full of expectations for future growth. 2. Moolec Science SA: up 10.93%, supported by the active performance of the biotechnology sector. 3. Davis Commodities: up 9.29%, benefiting from volatility in the commodities market. 4. UiPath: up 9.29%, driven by increasing demand for automation technology. 5. Brand Engagement Network: up 8.34%, with growing market interest in brand engagement technology. Stocks under pressure: 1. Symbotic: down 12.06%, facing pressure due to the divergence in the technology sector

    Tracking Unusual Activity·
    US
    AKTX
    0.00%
    Tracking Unusual Activity·
    US
    AKTX
    0.00%

    U.S. stock night trading volatility: Akari Therap plummeted 11.50% in after-hours trading, with active capital flow, and sector volatility has attracted market attention

    Akari Therap fell 11.50% in after-hours trading; Capricor fell 7.88%, with a trading volume of USD 340,600; Kala Pharmaceuticals rose 23.24%, with a trading volume of USD 107,200; Recursion Pharmaceuticals fell 0.64%, with a trading volume of USD 65,900

    Tracking Unusual Activity·
    US
    AKTX
    0.00%
    Tracking Unusual Activity·
    US
    AKTX
    0.00%

    European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading

    European equities traded in the US as ADRs rose 0.47% on the S&P Europe Select ADR Index. Leading gainers included Sequans Communications and Equinor, while Autolus Therapeutics and NuCana led decliners. Akari Therapeutics and Trinity Biotech also saw significant drops. MT Newswires cautions against unauthorized reproduction.

    fidelity·
    US
    AUTL
    +6.08%
    US
    AKTX
    0.00%
    US
    NCNA
    +4.48%
    fidelity·
    US
    AUTL
    +6.08%
    US
    AKTX
    0.00%
    US
    NCNA
    +4.48%

    U.S. stock night trading fluctuations: Akari Therap rose 3.65% in night trading, with active capital flow, and sector trends triggered volatility attention

    Akari Therap rose 3.65% in after-hours trading; Recursion Pharmaceuticals rose 1.62% in after-hours trading, with a transaction volume of USD 295,600; Moderna rose 0.42% in after-hours trading, with a transaction volume of USD 171,700; Jasper Therapeutics fell 8.86% in after-hours trading, with a transaction volume of USD 97,100

    Tracking Unusual Activity·
    US
    AKTX
    0.00%
    Tracking Unusual Activity·
    US
    AKTX
    0.00%
    © 2025 Longbridge｜Disclaimer